Warner Chilcott PLC
http://www.wcrx.com/index.jsp
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Warner Chilcott PLC
Seelos Aims For Conservative Approach After ALS Drug Shows Efficacy Signal
CEO Raj Mehta told Scrip Seelos anticipates conducting a Phase III study of SLS-005 after the cohort in HEALEY ALS failed overall, but indicated some efficacy in patients not receiving Relyvrio.
Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
Company Information
- Other Names / Subsidiaries
-
- Galen Holdings PLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice